Among the cancer cell lines used in this study, both CNE2-S18 and CNE1 cell lines were previously confirmed to have hyper-activated PI3K/AKT signaling due to the PIK3CA and HRAS mutation, respectively. The gene discussed is PIK3CA; the disease is cancer.